Moderna (MRNA) has rebounded ahead of a key cancer therapy data release. Over the last two U.S. trading sessions, the stock gained 4.07% and 6.69%, bringing the combined advance to about 11.04%. It last closed at $242.08 and reached an intraday high of $243.98. On Hyperliquid, the corresponding contract traded at $241.07, up about 5.71% over the past 24 hours.
Phase 3 readout set for ESMO
A major catalyst behind the move is the upcoming detailed Phase 3 data release for intismeran autogene, the personalized mRNA cancer therapy being developed jointly by Moderna and Merck. According to the company schedule, the two firms will present results from the INTerpath-001 Phase 3 study in high-risk melanoma at the European Society for Medical Oncology, or ESMO, meeting at 22:30 Beijing time on Oct. 24. An investor event is scheduled for 01:00 on Oct. 25.
The presentation is being watched as a detailed follow-up to previously announced positive results. On Aug. 19, the companies said the therapy in combination with Keytruda met the primary endpoint of recurrence-free survival, or RFS, and the key secondary endpoint of distant metastasis-free survival, or DMFS. Investors are expected to focus this weekend on the size of the benefit, the safety profile, and what the data may indicate for development in other cancers.
Stock has already priced in strong expectations
Since Aug. 18, the close of the trading session before those positive results were announced, MRNA has climbed about 284.5%. The share price has already reflected strong optimism around the company’s cancer pipeline. Even with the broader biotech sector performing well, MRNA still fell 7.82% in a single session last Friday, and the rebound over the past two sessions also marks a recovery from that pullback.
Wall Street firms have continued to raise valuation targets, though they have not moved in lockstep to chase the rally. Bank of America recently lifted its price target on Moderna to $220 from $200 and kept a neutral rating. The bank said the key focus at ESMO will be the actual magnitude of benefit from the combination therapy and whether the results can serve as a reference point for later studies in kidney cancer, bladder cancer, and other indications. Even after the increase, the $220 target remains about 9.1% below Moderna’s latest closing price of $242.08.
Whale short approaches liquidation
As the stock continues to trade near recent highs, a whale holding a short position worth about $4.52 million is nearing liquidation. According to TradingBeats monitoring, an address beginning with 0x4e23 is currently short about 18,700 MRNA contracts with 10x isolated leverage. The position is valued at about $4.518 million, with an average entry price of $237.04 and an unrealized loss of about $75,500.
The estimated liquidation price is $248.37, only about 3.03% above the current mark price, a gap of roughly $7.30. The trader also has three standard limit buy orders resting between $235.48 and $236.48, totaling about 3,522.98 contracts, or about $831,900, in an apparent attempt to exit around breakeven.


